Abstract Number: 2025 • ACR Convergence 2023
Osteoporosis Treatment Attributes and Levels for an Online Decision-Making Tool for Patients: Findings from Adaptive Choice-Based Conjoint Analysis
Background/Purpose: Osteoporosis (OP) treatment options have different attributes based on mode of administration, frequency of administration, risks of minor and serious side effects, and effectiveness,…Abstract Number: 2003 • ACR Convergence 2023
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…Abstract Number: 2004 • ACR Convergence 2023
Bone Health Following Bariatric Surgery: A Single Center Quality Improvement Study
Background/Purpose: Osteoporosis related fractures cause significant morbidity and mortality. Bariatric weight loss surgery is an independent risk factor for osteoporosis. Post-surgery dual energy X-Ray absorptiometry…Abstract Number: 2138 • ACR Convergence 2023
Frailty Is a Predictor of Incident Osteoporotic Fractures in Veterans with Rheumatoid Arthritis
Background/Purpose: Frailty occurs prematurely in RA. Levels of frailty are higher in Veteran populations than civilians1. Frailty has been shown to predict osteoporotic fractures in…Abstract Number: 2005 • ACR Convergence 2023
Secondary Prevention of Osteoporosis in Hip Fracture Care for Elderly Patients. Clinical and Functional Profile of Users
Background/Purpose: Osteoporosis is a first-rate problem in an increasingly ageing population. Falls among the elderly are a severe geriatric syndrome with relevant secondary effects. Fractures…Abstract Number: 2429 • ACR Convergence 2023
Romosozumab versus Denosumab in High-risk Patients Treated with Glucocorticoids: Interim 12-month Results from a Pilot Randomized Controlled Trial
Background/Purpose: To compare the efficacy and safety of romozosumab (ROMO) and denosumab (DEN) in high-risk patients treated with glucocorticoids (GCs). Methods: Adult patients (≥18 years)…Abstract Number: 2006 • ACR Convergence 2023
Improvement of Care: Osteoporosis Screening in a Resident-led Primary Care Clinic
Background/Purpose: Osteoporotic fractures, especially hip fractures, are associated with significant morbidity, including limitations in ambulation, disability, and decreased quality of life. The aim of this…Abstract Number: 2527 • ACR Convergence 2023
Risk Factors for Bone Loss in Systemic Lupus Erythematosus
Background/Purpose: Osteoporotic fractures are the most common damage item from the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index. Previous…Abstract Number: 1072 • ACR Convergence 2023
Increase in Major Osteoporotic Fractures After Therapy with Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of cancer. Despite their efficacy on tumor outcomes they can cause severe and sometimes long-standing immune-related…Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…Abstract Number: 2528 • ACR Convergence 2023
Current Trends in the Risk of Subsequent Fracture After Initial Fracture, and Post-Fracture Treatment Among Commercially Insured Postmenopausal Women in the United States
Background/Purpose: Recent studies suggest that post-fracture pharmacologic management has been declining in the U.S. despite an increase in the burden of osteoporosis (OP). In light…Abstract Number: 1098 • ACR Convergence 2023
Improving Osteoporosis Screening in Patients with Polymyalgia Rheumatica and Giant Cell Arteritis
Background/Purpose: Osteoporosis is a medical condition associated with decreased bone mass and bone architecture, which increases incidence of fragility fractures(4). It is associated with 1.5…Abstract Number: 2008 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking…Abstract Number: 2529 • ACR Convergence 2023
Comparative Effectiveness of Denosumab versus Zoledronic Acid Among Postmenopausal Women with Osteoporosis in the U.S. Medicare Program
Background/Purpose: Although clinical trials have shown that denosumab (Dmab) significantly increases bone mineral density at key skeletal sites more than zoledronic acid (ZA), evidence from…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 20
- Next Page »